This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trevena Granted Key Composition Of Matter Patent For TRV027 In U.S.

Stocks in this article: FRX

KING OF PRUSSIA, Pa., July 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that the United States Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027.  United States Patent No. 8,486,885 entitled "Beta-Arrestin Effectors and Composition and Methods of Use Thereof," is expected to provide coverage for TRV027 until at least July 2031.    

TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials.  It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that combines the proven benefits of angiotensin blockade with new beta-arrestin-mediated biology to preserve cardiac and renal function.  Trevena recently entered into a collaborative licensing option agreement for the development of TRV027 with Forest Laboratories Inc. (NYSE:FRX).  The company expects to commence a 500-patient multi-center Phase 2b clinical trial for TRV027 in ADHF patients by year end.

"This core patent provides the foundation for broad and enforceable intellectual property protection for TRV027, and is followed by a series of patent applications made by Trevena to protect our growing pipeline of GPCR biased ligands in key markets around the world,"  said Maxine Gowen, Trevena's President and Chief Executive Officer.  David Solomon, Forest's SVP of Corporate Development & Strategic Planning, and a Board member at Trevena, added, "This issued patent enhances the value potential of TRV027, and provides an essential platform from which to drive its commercialization."  

Trevena recently presented the results of a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction ( NCT01187836), as a poster at the American College of Cardiology meeting in March 2013. The Phase 2a trial was an ascending dose titration study in patients with stable NYHA Class 3 or 4 heart failure.   

About ADHFThe American Heart Association estimates that ADHF hospitalization costs the U.S. healthcare system more than $20 billion each year in direct spending.  ADHF is already the leading reason for hospitalization of individuals over 65 years old in the United States, with more than 1 million hospital admissions per year.  ADHF is also the most costly diagnosis for Medicare in the nation.  Despite the significance of this problem, current therapies are not producing meaningful improvements in patient outcomes.  ADHF incidence is increasing globally, and both heart failure mortality and hospital re-admission following an ADHF event remain extremely high.

About Trevena Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of GPCR targeted medicines.  GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation.  Trevena's expertise lies in engineering " biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects.  In addition to TRV027, Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and earlier-stage programs for chronic pain, and Parkinson's disease.  For more details, visit www.Trevenainc.com.

About Forest LaboratoriesForest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine.  Forest's pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas.  The Company is headquartered in New York, NY.  To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.  Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.

For more information, please contact: Rosamond Deegan, Vice President, Business Development 610-354-8840 x225 (Corporate Inquiries) Kimberly Minarovich, Christensen, 917-533-3268 (Media Inquiries)

SOURCE Trevena, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,863.94 +85.79 0.48%
S&P 500 2,075.02 +13.79 0.67%
NASDAQ 4,775.3820 +26.9860 0.57%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs